Press Releases April 5, 2026 08:00 PM

Inspire Medical Systems, Inc. to Report First Quarter 2026 Financial Results on May 4, 2026

Inspire Medical Systems Announces Q1 2026 Earnings Release Date and Conference Call

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
INSP

Inspire Medical Systems, Inc. will report its first quarter financial results for 2026 after market close on May 4, 2026, followed by a management conference call to discuss the company’s performance and business developments.

Inspire Medical Systems, Inc. to Report First Quarter 2026 Financial Results on May 4, 2026
INSP
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Earnings release scheduled for May 4, 2026, after market close.
  • Conference call for investors and analysts to discuss results and recent developments.
  • Company specializes in innovative, minimally invasive treatments for obstructive sleep apnea, with FDA and international approvals.

MINNEAPOLIS, April 06, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the first quarter 2026 after the close of trading on Monday, May 4. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q1 2026 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Inspire's Q1 2026 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. 

Following the call, a replay will be available on the Company's Investor Relations website approximately two hours after the event and archived on the site for two weeks.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
[email protected]
617-549-2443


Risks

  • Financial results may not meet market expectations leading to stock price volatility.
  • Uncertainties related to the adoption and commercialization of their neurostimulation technology.
  • Potential regulatory or competitive risks impacting future growth and market penetration.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026